Scarica l'app Stockscreener
34.50
4.98%
-1.81
Precedente Chiudi:
$36.31
Aprire:
$36.31
Volume 24 ore:
199.01K
Relative Volume:
0.46
Capitalizzazione di mercato:
$1.85B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-18.80%
1M Prestazione:
+0.00%
6M Prestazione:
+237.57%
1 anno Prestazione:
+282.91%
Intervallo 1D:
$34.05
$36.64
Intervallo di 1 settimana:
$34.05
$42.69
Portata 52W:
$5.83
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Nome
Zenas Biopharma Inc
Settore
Industria
Telefono
857-271-2954
Indirizzo
852 WINTER STREET, SUITE 250, WALTHAM
Confronta ZBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
34.50 | 1.95B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-20 | Iniziato | Wedbush | Outperform |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus - ts2.tech
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus - ts2.tech
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.4%Here's Why - MarketBeat
Is Zenas BioPharma Inc. stock attractive after correctionCandlestick Pattern Analysis & Small Capital Gains - bollywoodhelpline.com
Zenas BioPharma, Inc (NASDAQ:ZBIO) Drives Innovation in Biologic Science - Kalkine Media
Zenas BioPharma : Corporate Presentation - marketscreener.com
Why Zenas BioPharma (ZBIO) Is Up 20.6% After Index Inclusion And ESOP Shelf Filing – And What's Next - Sahm
Analysts' Revenue Estimates For Zenas BioPharma, Inc. (NASDAQ:ZBIO) Are Surging Higher - simplywall.st
Zenas BioPharma (NASDAQ:ZBIO) Hits New 52-Week HighWhat's Next? - MarketBeat
Zenas BioPharma (ZBIO) Valuation Check as Investors Position for Obexelimab Phase 3 IgG4 Data - Sahm
Zenas Biopharma stock reaches all-time high of 41.67 USD By Investing.com - Investing.com Nigeria
Zenas BioPharma (NASDAQ:ZBIO) Trading 8.9% HigherShould You Buy? - MarketBeat
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next - ts2.tech
Zenas Biopharma stock reaches all-time high of 41.67 USD - Investing.com India
Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says - marketscreener.com
Wedbush Reiterates Outperform Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to NASDAQ Biotechnology Index - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2025-12-21 | Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation | NDAQ:ZBIO | Press Release - Stockhouse
How interest rate cuts could boost Zenas BioPharma Inc. stockRecession Risk & Weekly Hot Stock Watchlists - ulpravda.ru
Zenas BioPharma approves 2026 inducement plan - MSN
Can Zenas BioPharma Inc. stock reach $100 price target2025 Risk Factors & Short-Term High Return Ideas - Улправда
Why Zenas BioPharma Inc. stock remains on buy listsJuly 2025 Technicals & Stepwise Swing Trade Plans - Улправда
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Winners Losers: What sentiment indicators say about Zenas BioPharma Inc. stock2025 Big Picture & Daily Entry Point Trade Alerts - Улправда
Growth Value: How interest rate cuts could boost Zenas BioPharma Inc. stockShare Buyback & Weekly High Return Stock Forecasts - Улправда
Zenas Biopharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Insider Trends: How interest rate cuts could boost Zenas BioPharma Inc. stock - Улправда
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Is Zenas BioPharma Inc. stock resilient to inflationJuly 2025 Retail & Step-by-Step Trade Execution Guides - DonanımHaber
What insider trading reveals about Zenas BioPharma Inc. stockJuly 2025 Chart Watch & Low Risk Entry Point Guides - DonanımHaber
New Highs: How interest rate cuts could boost Zenas BioPharma Inc. stockTrade Risk Summary & Risk Controlled Stock Alerts - Улправда
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Earnings Report: Is Zenas BioPharma Inc stock a bargain at current levelsJuly 2025 Earnings & Free Community Supported Trade Ideas - moha.gov.vn
Orelabrutinib’s SLE Phase 2b Success Could Be A Game Changer For Zenas BioPharma (ZBIO) - Sahm
H.C. Wainwright reiterates Buy rating on Zenas Biopharma stock amid competitor setback - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Trading 6.7% HigherTime to Buy? - MarketBeat
Zenas BioPharma Shares Surge Amid Promising Drug Trials - TipRanks
Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential - TipRanks
Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside - TipRanks
Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod - Indian Pharma Post
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Zenas BioPharma (ZBIO): Reassessing Valuation After Orelabrutinib’s Phase 2b Lupus Success and China Phase 3 Green Light - Yahoo Finance
Zenas BioPharma (ZBIO): Reassessing a Rich Valuation After Positive Orelabrutinib Lupus Trial Milestones - Sahm
Zenas BioPharma Approves 2026 Inducement Plan - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 9.9%Should You Sell? - MarketBeat
ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How - GuruFocus
Zenas BioPharma falls -13.0% - TipRanks
InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib - TipRanks
Innocare Pharma announces achievement of primary endpoint in phase 2b study of orelabrutinib - marketscreener.com
Zenas Biopharma Inc Azioni (ZBIO) Dati Finanziari
Non sono disponibili dati finanziari per Zenas Biopharma Inc (ZBIO). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Zenas Biopharma Inc Azioni (ZBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Oct 09 '25 |
Buy |
19.00 |
126,315 |
2,399,985 |
1,917,895 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
19.00 |
105,265 |
2,000,035 |
1,832,669 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
20.85 |
11,990 |
249,992 |
11,990 |
| MOULDER LEON O JR | See Remarks |
Oct 07 '25 |
Buy |
20.85 |
36,928 |
769,949 |
36,928 |
| Fairmount Funds Management LLC | Director |
Oct 07 '25 |
Buy |
19.00 |
316,219 |
6,008,161 |
2,209,025 |
| Lu Hongbo | Director |
Oct 07 '25 |
Buy |
19.00 |
263,160 |
5,000,040 |
321,983 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 18 '25 |
Buy |
6.67 |
25,000 |
166,750 |
266,155 |
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):